Clinical Trials Directory

Trials / Completed

CompletedNCT01592734

Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children

Efficacy and Tolerability of PEG-only Laxative for Fecal Impaction and Chronic Constipation in Children. A Controlled Double Blind Randomized Study vs a Standard PEG-EL Laxative

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
96 (actual)
Sponsor
Azienda Policlinico Umberto I · Academic / Other
Sex
All
Age
2 Years – 16 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to compare the efficacy, tolerability, acceptance and compliance of a PEG-only formulation compared to a reference PEG-EL formulation in resolving faecal impaction and in the treatment of chronic constipation

Detailed description

Constipation is a very common complaint in childhood. Inadequate daily fiber intake, insufficient fluid intake, and withholding behavior are considered as factors leading to constipation. Painful defecation is considered a common trigger to faecal retention wich leads to reabsorption of fluids and increase in the size and consistency of stools. It is often necessary to use laxative therapy to achieve comfortable defecation. PEG-based laxatives are considered today the gold standard for treatment of constipation in children. PEG formulations differ for composition in inactive ingredients which may have an impact on acceptance, compliance and adherence to treatment.

Conditions

Interventions

TypeNameDescription
DRUGPolyethylene glycol with electrolytesConstipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks. Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days.
DEVICEPolyethylene glycolConstipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children \> 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks. Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days.

Timeline

Start date
2010-05-01
Primary completion
2011-11-01
Completion
2011-11-01
First posted
2012-05-07
Last updated
2012-05-07

Source: ClinicalTrials.gov record NCT01592734. Inclusion in this directory is not an endorsement.